Shire’s ADHD treatment Vyvanse won a label expansion into treating moderate-to-severe binge-eating disorder (BED) Friday. One analyst says that disease awareness and detailing efforts are crucial to the drug’s commercial plans in the category.
Attendance by physicians crept up in 2012, said the trade group HCEA, but overall turnout was flat, likely because exhibitors brought less personnel along to meetings.
The FDA’s opioid REMS safety plan is challenged on two fronts: getting CME providers to offer courses and getting doctors to attend them. Can the agency’s scheme educate enough physicians to curb an epidemic?
Samples no longer hold sway in pharma marketing mix: study